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AbstrAct
Purpose To estimate the Australian cancer burden 
attributable to lifestyle-related risk factors and their 
combinations using a novel population attributable fraction 
(PAF) method that accounts for competing risk of death, 
risk factor interdependence and statistical uncertainty.
Participants 365 173 adults from seven Australian 
cohort studies. We linked pooled harmonised individual 
participant cohort data with population-based cancer 
and death registries to estimate exposure-cancer and 
exposure-death associations. Current Australian exposure 
prevalence was estimated from representative external 
sources. To illustrate the utility of the new PAF method, 
we calculated fractions of cancers causally related to 
body fatness or both tobacco and alcohol consumption 
avoidable in the next 10 years by risk factor modifications, 
comparing them with fractions produced by traditional PAF 
methods.
Findings to date Over 10 years of follow-up, we observed 
27 483 incident cancers and 22 078 deaths. Of cancers 
related to body fatness (n=9258), 13% (95% CI 11% 
to 16%) could be avoided if those currently overweight 
or obese had body mass index of 18.5–24.9 kg/m2. Of 
cancers causally related to both tobacco and alcohol 
(n=4283), current or former smoking explains 13% 
(11% to 16%) and consuming more than two alcoholic 
drinks per day explains 6% (5% to 8%). The two factors 
combined explain 16% (13% to 19%): 26% (21% to 30%) 
in men and 8% (4% to 11%) in women. Corresponding 
estimates using the traditional PAF method were 20%, 
31% and 10%. Our PAF estimates translate to 74 000 
avoidable body fatness-related cancers and 40 000 
avoidable tobacco- and alcohol-related cancers in 
Australia over the next 10 years (2017–2026). Traditional 
PAF methods not accounting for competing risk of death 
and interdependence of risk factors may overestimate 
PAFs and avoidable cancers.
Future plans We will rank the most important causal 
factors and their combinations for a spectrum of cancers 
and inform cancer control activities.
IntroductIon
Cancer is the leading cause of disease burden 
and death in Australia.1 2 One of the prin-
cipal strategies for reducing this burden is 
to target the key preventable causal factors, 
focusing activities where the association is 
strong, the exposure is common, and by 
considering the combination of both these 
factors overall and in population subgroups. 
The disease burden measure population 
attributable fraction (PAF) can be used to 
estimate the proportion of cancers that could 
be prevented if exposure to its risk factors 
were removed or reduced.3 4 PAF accounts 
for both the strength of the exposure-cancer 
association and the exposure prevalence in 
Strengths and limitations of this study
 ► A large, population-based, pooled prospective cohort 
with broad demographic and geographical coverage 
and individual participant data.
 ► Risk factor exposure prevalence estimates obtained 
from representative contemporary data sources to 
enhance the accuracy of population attributable 
fraction (PAF) estimates.
 ► The first cancer-PAF estimates from large-scale 
cohort study data that account for competing risk 
of death.
 ► Cancer-PAF estimates for the simultaneous effects 
of multiple risk factors, thereby accounting for their 
interdependence.
 ► CIs computed to show uncertainty in PAF estimates 
and differences between population subgroups.
 ► Estimates of the future numbers of cancers in 
Australia preventable by adherence to current 
recommendations for a healthy lifestyle.
 ► Evidence to underpin future evaluations of potential 
public health policies and interventions designed to 
reduce the cancer burden.
 ► Further improvements in the PAF methods are 
needed to incorporate the time the risk factor 
modification takes to be realised and the uncertainty 
in the exposure prevalence estimates.
 ► Larger cohort populations are needed to provide 
reliable data on some of the rarer cancers, cancer 
subtypes, risk factor combinations and population 
subgroups.
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the population of interest. PAFs are increasingly used 
to evaluate the national, regional and global burden 
of cancer and to advocate for changes in public health 
policy and activity settings to reduce the prevalence of 
causal risk factors.5 However, limitations in both the avail-
able data and the methods used restrict the accuracy of 
the PAF estimates and the scope of the conclusions.
Most prior cancer-PAF studies have relied on published 
exposure-cancer associations. As risk factor interaction 
and population subgroup analyses are rarely available, 
overall PAF estimates for individual risk factors domi-
nate the literature.6 Even where estimates are available, 
differences in the measurement and categorisation of 
risk factors and modelling approaches may limit their 
comparability. Most studies that have estimated PAFs for 
combined effects of risk factors have assumed indepen-
dence between carcinogenic exposures.5 7 8 Yet, in reality, 
modifiable lifestyle-related risk factors can interact to 
cause cancer and their effect may be higher for certain 
subgroups.9 Moreover, these risk factors tend to co-occur 
or cluster, further adding to the burden of both cancer 
and death, and the effect of modifying one risk factor 
may be mediated by changes in other risk factors.9–11
PAFs are best estimated from cohort studies in which 
the risk factor exposure measurement precedes the 
cancer incidence.12 Cohort studies also allow ascertain-
ment of multiple outcomes related to an exposure and 
thus permit analyses to account for potential competing 
risks, such as death, which can alter PAF results.13 To our 
knowledge, no previous cancer-PAF study has accounted 
for competing risk of death. This can be critical for 
cancers where established risk factors also predict risk 
of death from other causes and risk factor modifications 
will thus affect both outcomes. In addition, most previous 
cancer-PAF cohort studies have estimated exposure prev-
alence from the cohort population even when it has not 
been sampled to be representative of the target popula-
tion of interest.14 This hinders both generalisation and 
comparison of the findings. Finally, CIs for PAF estimates 
are often not provided, precluding an evaluation of 
their precision and also differences between population 
subgroups.
We addressed these deficiencies by applying our 
method13 15 for estimating PAF and its CI for cancer inci-
dence, allowing analysis of the simultaneous effects of 
multiple factors and accounting for competing risk of 
death, to an Australian cohort consortium and represen-
tative external exposure prevalence data.
cohort consortIum descrIptIon
Australian cancer-pAF cohort consortium
The eligibility criteria for inclusion in the consortium 
were: well-established population-based Australian 
prospective cohort studies with comprehensive informa-
tion on modifiable lifestyle-related exposures at baseline. 
Seven cohort studies met these criteria: Melbourne 
Collaborative Cohort Study (MCCS),16 Blue Mountains 
Eye Study (BMES),17 Australian Longitudinal Study 
on Women’s Health (ALSWH),18 Australian Diabetes, 
Obesity and Lifestyle Study (AusDiab),19 North West 
Adelaide Health Study (NWAHS),20 Concord Health 
and Ageing in Men Project (CHAMP)21 and 45 and Up 
Study (45&Up).22 Together they formed a study sample 
of 369 515 adult Australians of different ages covering the 
adult lifespan (table 1). Pooling of the cohorts identified 
2457 people enrolled in more than one cohort, leaving 
a final population of 367 058 individuals, 365 173 with 
consent for record linkage.
The cohorts recruited participants between 1990 and 
2009 (table 1). Only one cohort, AusDiab with recruitment 
from 1999, was designed to include a sample represen-
tative of the Australian population. Therefore, we used 
the latest representative external data sources to obtain 
contemporary age- and sex-specific risk factor prevalence 
estimates. These sources included the National Health 
Surveys (NHS) conducted 2014–2015 (NHS3),23 2004-
2005 (NHS2)24 and 2001 (NHS1),25 the National Drug 
Strategy Household Survey (NDSHS) conducted in 201326 
and the Learning how Australians Deal with menopausal 
sYmptoms (LADY) Survey conducted in 201327 (tables 1, 
2 and 3), for which de-identified unit record data were 
available to generate the required exposure prevalences.
data collection and harmonisation
All cohort studies collected baseline information on 
demographic, medical, lifestyle-related and hormonal 
exposures through self-completed questionnaires and 
some also through interviews and medical examinations 
(MCCS, BMES, AusDiab, NWAHS and CHAMP). We 
harmonised all available information on the relevant 
exposures across the cohort studies and the external data 
sources to the greatest extent possible (tables 2 and 3).
The modifiable exposures examined were regular 
smoking, alcohol consumption, body fatness (BMI ≥25 kg/
m2), physical activity, fruit consumption, vegetable 
consumption, red and processed meat consumption, oral 
contraceptive (OC) use, menopausal hormone therapy 
(MHT) use and breastfeeding. We classified the lifestyle 
exposures to match current Australian recommendations 
for healthy living, that is, not smoking, drinking no more 
than two standard alcoholic drinks per day (ie, 20 g of 
alcohol per day), maintaining healthy weight (BMI 18.5–
24.9 kg/m2), doing at least 150 min of moderate or 75 min 
of vigorous physical activity per week, eating at least two 
serves (ie, 300 g) of fruits and five serves (ie, 375 g) of 
vegetables per day, and not eating more than two serves 
(130 g) of either red or processed meat 3–4 times a week 
(table 2).
We also harmonised non-modifiable exposures such 
as age, gender, height, country of birth, marital status, 
education, socioeconomic status, urban–rural status, 
health insurance, reproductive history and personal and 
family medical history to allow population subgroup 
analyses and assessment of potential confounding factors 
(table 3).
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We linked the pooled cohort to the population-based 
Australian Cancer Database (ACD) and National Death 
Index (NDI) to identify cancers and deaths. The ACD is 
a database of all primary, malignant cancers, except kera-
tinocyte cancers, notified to State and Territory Cancer 
Registries in Australia since 1982. The NDI records 
all deaths registered in Australia since 1980. Both the 
ACD and NDI are maintained by the Australian Insti-
tute of Health and Welfare, which facilitates research by 
conducting record linkage using an established probabi-
listic linkage algorithm.28
In October 2016, the ACD and NDI records were avail-
able until the end of 2012, providing 8–22 years follow-up 
depending on the individual cohort (table 1).
data analysis and statistical methods
We classified cancers on the basis of the International 
Classification of Diseases for Oncology codes. Only inva-
sive cancers identified by data linkage were included, and 
people with a cancer registration prior to baseline were 
excluded from the analysis for that malignancy.
We defined follow-up as the time from baseline to 
the date of diagnosis of the cancer of interest, death or 
end of follow-up, whichever occurred first. The survival 
times were assumed to follow a parametric proportional 
hazards model with piecewise constant baseline hazard 
function.29 Maximum likelihood estimation with itera-
tive methods was used to obtain the parameter estimates 
and their estimated covariance matrices.13 We expressed 
the strength of exposure-cancer and exposure-death 
associations adjusted for baseline age, sex and study as 
HRs and their 95% CIs. We computed the corresponding 
age- and sex-specific exposure prevalence estimates from 
the most contemporary representative external data 
source. Participants with missing data for the variables 
included in the model were excluded from the analyses. 
We then combined the maximum likelihood estimates 
and the exposure prevalence estimates to calculate the 
PAF point estimates using our recently developed PAF 
formula13 accounting for competing risk of death. The 
asymptotic variance estimate of PAF was obtained using 
the delta method, and two-sided 95% CIs for the PAFs 
were calculated by applying a symmetrising comple-
mentary logarithmic transformation of PAF.13 Our PAF 
method13 and program15 allows a flexible choice of the 
reference level for the hypothetical risk factor modifica-
tion and simultaneous analysis of the effects of multiple 
risk factors. Both individual PAFs for modification of 
single risk factors and joint PAFs for modification of 
several risk factors can be calculated.
To illustrate the novel cancer-PAF estimation, we esti-
mated the fractions of cancers causally related to (1) body 
fatness and (2) both tobacco and alcohol consumption 
attributable to these risk factors in Australia over the next 
10 years. We restricted these analyses to the first 10-year 
follow-up to generate comparable estimates across the 
cohorts. We included only those cancers judged by 
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the International Agency for Research on Cancer to 
be causally associated with body fatness (oesophageal 
adenocarcinoma, stomach, colorectal, liver, gallbladder, 
pancreas, postmenopausal breast, corpus uteri, ovary, 
renal-cell carcinoma, meningioma, thyroid and multiple 
myeloma) or with both tobacco and alcohol consump-
tion (tongue, mouth, oropharynx, hypopharynx, 
other pharynx (excluding nasopharynx), oesophagus, 
colorectal, liver and larynx).30 31 It should be noted that 
cancers of the lung and breast are not included here as 
they are not causally related to both tobacco and alcohol 
consumption. We estimated the individual contribu-
tion of body fatness, tobacco and alcohol consumption 
and the combined contribution of tobacco and alcohol 
consumption on the burden of the respective cancers. 
For body fatness, we evaluated scenarios in which (1) 
those currently obese or overweight had healthy weight 
and (2) those currently obese were overweight. For 
smoking, we evaluated scenarios in which (1) current 
and former smokers had never smoked and (2) current 
smokers were to quit and become former smokers. For 
alcohol consumption, we evaluated the scenario in which 
no-one drank more than two alcoholic drinks per day. 
We also evaluated potential effect modification of the 
contribution of smoking by alcohol consumption and all 
three risk factors by sex. We estimated the numbers of 
these cancers that could be avoided in Australia under 
these scenarios by multiplying the PAF estimates by the 
projected numbers of cancers over the next 10 years 
(2017–2026).32 33
To demonstrate the potential impact of our method-
ology on PAF estimates, we compared our results with PAF 
estimates produced by traditional methods,3 4 adapted 
to cohort studies with survival data by replacing the rela-
tive risks (RRs) in the original formulas by HRs from 
survival models34 that do not account for competing risk 
of death and that take a sequential approach to estimate 
the combined effect of multiple risk factors, assuming 
their independence.7 14
We carried out all statistical analyses using SAS V.9.4 
and a publicly available PAF program based on SAS 
macros.15
FIndIngs to dAte
harmonisation and prevalence of lifestyle-related risk 
factors
Smoking, alcohol consumption and body fatness could 
be harmonised for all cohorts, while physical activity, fruit 
and vegetable consumption, red and processed meat 
consumption, OC and MHT use and breastfeeding were 
either not collected at baseline or could not be harmon-
ised for some cohorts (table 2).
The participant age and sex distribution varied across 
the cohorts (table 1) as did the crude risk factor expo-
sure prevalences (table 4), even in cohorts recruited 
around the same time. The sex- and age-stratified expo-
sure prevalence estimates were more comparable but 
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generally lower for the cohort studies than the represen-
tative external data sources from around the same time 
(see online supplementary table 1).
Exposure prevalence estimates from the representa-
tive external sources (NHS 2001, 2004 and 2014–2015; 
table 4) showed different temporal trends depending 
on specific risk factors. The overall prevalence (men and 
women) of current smoking decreased over time (22%, 
21%, and 15%, respectively). The overall prevalence of 
consuming more than two alcoholic drinks a day (19%, 
22% and 17%) and inadequate fruit consumption 
(48%, 46% and 50%) were relatively stable over time. 
The prevalence of body fatness (50%, 54% and 63%), 
physical inactivity (52%, 61% and 74%) and inadequate 
vegetable consumption (70%, 86% and 91%) increased 
over time. Currently, the prevalence of many modifiable 
lifestyle-related risk factors exceeds 50% of Australians 
and is generally higher in men than women (table 4).
The variable cohort age and sex distribution and 
the temporal trends in exposure prevalences demon-
strate the need to use representative and most recent 
prevalence estimates for reliable PAF calculations. Red 
and processed meat consumption were the only expo-
sures that could not be obtained from a representative 
external source (tables 2 and 3); we obtained these prev-
alence estimates from the largest and latest cohort (The 
45 and Up Study) and will perform sensitivity analyses 
to assess the impact of the uncertainty in this measure.
cancer and death cases in the pooled cohort
During the maximum 22-year follow-up of the pooled 
cohort (n=365 173; table 1) with mean age 59 years and 
59% women, 35 860 incident cancers and 32 107 deaths 
were observed (see online supplementary table 2). The 
distribution of the cancers in the pooled cohort is similar 
to that for the Australian population.2 During the first 
10-year follow-up, we observed 27 483 cancers and 22 078 
deaths. There were 9258 participants with a first primary 
cancer causally related to body fatness and 4283 partici-
pants with a first primary cancer causally related to both 
tobacco and alcohol (see online supplementary table 3). 
No significant heterogeneity between the cohort-specific 
HRs for cancers causally related to body fatness or both 
tobacco and alcohol was found (see online supplemen-
tary table 4).
Avoidable cancers causally related to body fatness, and both 
tobacco and alcohol
Individual and combined contributions of risk factors
According to our estimations, overweight and obesity 
(table 5) explain 13% (95% CI 11% to 16%) of the 
10-year burden of cancers causally associated with body 
fatness (table 6). If those currently obese were over-
weight, 5% (95% CI 3% to 7%) of the burden could be 
avoided. For cancers causally related to both tobacco 
and alcohol consumption, 13% (95% CI 11% to 16%) is 
attributable to smoking and could be avoided if current 
and former smokers had never smoked (table 6). If 
current smokers were to quit, 3% (95% CI 1% to 4%) 
of the burden could be avoided. Drinking more than 
two alcoholic drinks per day explains 6% (95% CI 5% 
to 8%) of the burden. Excessive alcohol consumption 
combined with ever smoking explains 16% (95% CI 
13% to 19%) and combined with current smoking 8% 
(95% CI 5% to 10%) of the burden of these cancers 
over the next 10 years. Current smokers who also 
consume more than two alcoholic drinks per day are 
at a significantly higher risk of these cancers compared 
with smokers whose alcohol consumption does not 
exceed two daily drinks (HR 2.09 vs 1.41; table 5) 
and would benefit much more from quitting smoking 
(PAF 9% (95% CI 4% to 15%) versus 1% (95% CI 0% 
to 3%)).
Contributions by sex
The contribution of body fatness to cancers causally 
related to this risk factor was 17% (95% CI 11% to 22%) 
for men and 12% (95% CI 9% to 15%) for women. The 
contribution of both smoking and excessive alcohol 
consumption to the burden of cancers causally related 
to both these exposures was even more pronounced for 
men (table 6). The PAFs for current and former smoking 
were 22% (95% CI 17% to 26%) for men versus 7% (95% 
CI 3% to 10%) for women and for consuming more than 
two alcoholic drinks per day 9% (95% CI 6% to 12%) 
versus 2% (95% CI 0% to 4%). Modifications to both of 
these risk factors could reduce the burden by 26% (95% 
CI 21% to 30%) for men and 8% (95% CI 4% to 11%) 
for women.
Comparison of novel and traditional PAF methods
Body fatness and alcohol consumption were weakly asso-
ciated with death from causes other than the cancers 
of interest, whereas smoking was a moderate risk factor 
for mortality during the 10-year follow-up (HR 1.36 for 
former smokers and 2.23 for current smokers). Accord-
ingly, the PAF estimates based on the novel and traditional 
methods differed most for smoking, especially for men 
(table 6). The differences between the two methods 
were larger when the combined effect of modifying both 
smoking and alcohol consumption was analysed. The 
point estimates given by the traditional method no longer 
fitted within the CIs produced by the novel method both 
for the overall population (20% vs 16% (95% CI 13% to 
19%) and for men (31% vs 26% (95% CI 21% to 30%); 
however, the lack of CIs around the traditional estimates 
makes direct comparison difficult.
Projected avoidable numbers of cancers
Based on the projected Australian cancer incidence rates 
over the next 10 years, around 840 000 people will be 
diagnosed with cancer, of which over 570 000 are cancers 
causally related to body fatness and 250 000 cancers caus-
ally related to both tobacco and alcohol consumption. Of 
these, according to our PAF estimates, 74 000 cases can 
be attributed to body fatness, 32 000 to smoking, 15 000 
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to consuming more than two alcoholic drinks per day 
and 40 000 to the latter two exposures combined. The 
number of cancers preventable through avoiding both 
smoking and excessive alcohol consumption are overes-
timated by 10 000 if the competing risk of death is not 




The large cohort and advanced PAF methodology 
enables analysis of both the individual and joint contri-
bution of risk factors to the burden of cancer, both 
overall and in subgroups. In the next stage of this 
research, we will identify and rank the most harmful 
cancer risk factors and their combinations for specific 
cancers and evaluate the distribution of their burden. 
We will also evaluate the contribution of different risk 
factors across all cancers. We will use this epidemiolog-
ical evidence to inform future health promotion and 
other cancer control activities.
Access to individual participant cohort data allowed 
us to harmonise risk factors, potential confounding 
factors and effect modifiers. This is expected to increase 
the comparability and accuracy of the PAF estimates. As 
recommended,35 we documented our rigorous guidelines 
for data harmonisation to enable reproducibility and use 
in subsequent pooling efforts. We aligned our exposure 
classifications with the Australian recommendations for 
maintaining a healthy lifestyle, allowing consistency of 
risk communication.
Utilising corresponding risk factor exposure prevalence 
estimates from representative data sources also increased 
the accuracy of our PAF estimates. Cohort studies may 
have variable age and sex distributions, and they may 
underestimate the exposure prevalence, likely due to a 
‘healthy participant’ bias,36 reinforcing the need to use 
representative age- and sex-specific exposure prevalence 
data in PAF calculations.
We provide the first Australian estimates on the 
potential future burden of cancer avoidable through 
modification of current harmful exposures, using the 
latest available exposure prevalence estimates. Expo-
sure to lifestyle-related risk factors is highly prevalent 
and largely increasing in Australia23 and internation-
ally,5 37 and thus lifestyle modifications can have a large 
impact on the cancer burden. The exception to these 
trends is current smoking, as Australia is a world leader 
in smoking control, and prevalence rates are low and 
continuing to fall.23 26 38 As we used the latest expo-
sure prevalence data and evidence on cancers causally 
associated with specific exposures, recently updated 
for body fatness,31 our PAF estimates are not directly 
comparable with previous Australian estimates.8 These 
estimates were also based on published, mostly inter-
national, exposure-cancer associations, whereas we use 
harmonised Australian cohort data.
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Accounting for competing risk of death is likely to have 
further increased the accuracy of our PAF estimates as 
ignoring competing risk of death can overestimate the 
fraction of cancers preventable by risk factor modifica-
tion.13 That is, if cancer and death share the same risk 
factors, reduction of these risk factors is likely to reduce 
the risk of cancer and the risk of death, and people living 
longer have increased opportunity to develop cancer. The 
bias is higher the more strongly the cancer risk factor is 
associated with death, the more risk factors are evaluated 
simultaneously and the longer the follow-up.13 Our PAF 
method also produced CIs for the PAF estimates, allowing 
an evaluation of their precision and statistical comparison 
of subgroup estimates.
Our PAF method also allows a flexible choice of 
the reference level for a risk factor modification (eg, 
reducing the risk of current smokers to the level of 
former smokers) and analysis of the simultaneous 
effects of multiple risk factors. We showed that the 
combined contribution of two exposures on the 
cancer burden was overestimated if their effects on 
mortality were not accounted for and were assumed 
to be independent. We found that even a relatively 
small difference in PAF estimates can translate into a 
large difference in the number of preventable cancers 
predicted. Compared with the traditional method, 
our PAF estimates are thus more likely to reflect the 
real-world impact of modifying one or more risk 
factors10 and to better inform future cancer control 
activities.
limitations
Some risk factors were not collected by all studies, not 
available in the baseline data or the information available 
was too different for harmonisation, and as a result these 
studies could not be included in all analyses, reducing the 
statistical power. Additionally, some risk factors varied in 
how well they could be harmonised due to different ques-
tion formulations and definitions (eg, ‘daily’ vs ‘regular’ 
smoking) or measurement methods (eg, self-reported 
vs measured BMI). Measurement error, both within and 
between studies, would generally lead to underestima-
tion of the respective associations and PAF estimates. 
Additionally, as the exposure prevalence trends over 
time demonstrate, exposure to risk factors measured 
at baseline may have changed during follow-up, which 
would have further contributed to underestimation of 
the respective associations and PAFs. Some cohort studies 
performed repeated measurements during follow-up; 
these measures could be incorporated in future analyses 
as our PAF method allows the inclusion of time-depen-
dent covariates.
Our illustrative PAF estimates for body fatness-re-
lated and tobacco and alcohol-related cancers were 
adjusted for age, sex and study and are thus subject 
to residual confounding by other risk factors affecting 
these associations. In the next stage of the project, 
we will compute cancer-specific PAF estimates and 
thoroughly evaluate and adjust for potential confounding 
factors.
The distribution of cancers in the cohort studies, 
especially when grouped, may not be the same as in the 
Australian population, and this may impact the general-
isability of the findings. Reassuringly, the rank order of 
individual cancers in our cohort was similar to that for the 
Australian population.2
Our risk factor exposure prevalence estimates were 
obtained from study populations sampled to be repre-
sentative of all Australians, but these surveys were 
limited in size and did not achieve 100% response rates, 
and therefore their representativeness is uncertain. For 
red and processed meat consumption, an important 
risk factor for several cancers, no prevalence informa-
tion from such data sources was available; this further 
emphasises the importance of reaching a consensus 
on question formulations and definitions for core risk 
factors. Furthermore, even though we used the latest 
available exposure prevalence data, the estimates still 
lag behind the present situation. Therefore, our PAFs 
may be either slightly underestimated or overesti-
mated, depending on the current exposure prevalence 
trends.
We note that probabilistic record linkage will have 
incurred a low rate of false positive and false nega-
tive matches, resulting in slight misclassification of 
the outcome.39 Also, we were not able to capture 
loss to follow-up, for example, due to participants 
leaving Australia. Each of these limitations will 
likely have resulted in bias towards the null and PAF 
underestimation.39
Although we provide improved PAF estimates, further 
improvements are possible. One major assumption in 
the PAF estimation is an immediate reduction in risk 
after the hypothetical modification of the exposure 
of interest. This is unrealistic and therefore all PAF 
estimates overestimate the effect of the risk factor 
modification, or rather the time required for that 
effect to take place. Once reliable evidence on the 
lag time between an intervention and reduction in 
risk is available, it can be incorporated in the estima-
tion of PAF using advanced modelling approaches.34 
The extent to which this is balanced by the various 
sources of underestimation mentioned above is not 
known and varies by risk factor. Furthermore, there is 
inherent uncertainty in the exposure prevalence esti-
mates that could be incorporated in the PAF estimation 
for example through resampling-based methods such 
as bootstrap that require access to individual-level 
survey data. Finally, despite the large database avail-
able via our consortium, we have insufficient power 
to provide robust estimates for some of the rarer 
cancers, cancer subtypes, risk factor interactions 
and population subgroups. We aim to overcome this 
limitation by establishing an international cancer-PAF 
consortium.
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Collaborators International cohort studies with risk 
factor, confounder and effect modifier, cancer and death 
data and access to representative up-to-date prevalence 
sources are welcome to participate. We encourage any 
interested parties to contact the corresponding author.
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